G1 Therapeutics, Inc. (GTHX) Tops Q4 EPS by 8c

G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q4 EPS of ($0.73), $0.08 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $10.25 million versus the consensus estimate of $9.84 million.

For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Xylem names Andrea van der Berg as CFO, effective Sept. 2026
• Raymond James sees positive earnings trends across market caps